Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
about
Magnesium for treating sickle cell diseaseMagnesium for treating sickle cell diseasePotential therapeutic action of nitrite in sickle cell diseaseTriarylmethanes, a new class of cx50 inhibitors.Effects of nitric oxide and its congeners on sickle red blood cell deformability.Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore.The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease.Clotrimazole as a Cancer Drug: A Short Review.KCa 3.1-a microglial target ready for drug repurposing?Effects of sidechain length and composition on the kinetic conversion and product distribution of vitamin D analogs determined by real-time NMR.KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.Pathophisiology of sickle cell disease and new drugs for the treatment.Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker seSenicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke.Nitric oxide pathology and therapeutics in sickle cell disease.Squeezing for Life - Properties of Red Blood Cell Deformability.Senicapoc trial results support the existence of different sub-phenotypes of sickle cell disease with possible drug-induced phenotypic shifts
P2860
Q24193246-9A17B85D-8D41-4B67-A23B-D38D37CEC2B9Q29994630-BB06859C-F519-42B1-B40A-3D508B00BADEQ33681568-B45779D1-AE75-4664-A478-B7AA1586101EQ34299455-E8D9EECB-2039-444F-801F-9F7979BE6CBBQ35614475-E795F147-05AB-427F-B6AE-7D573D3EDF76Q35944615-30058DD1-9F39-4373-A7F6-B16608327529Q36261948-11C4F9B7-A52C-4B02-B506-41E68E5966B1Q36438976-699DC6A3-5BD6-4E62-AB0A-D6F8FFF301F2Q36815916-DBA8D472-55A3-4F78-BB45-6B6E96A19A3FQ38714666-DBE14EF2-A3B8-40E1-96A5-E63E0688B497Q38819263-A3C39B00-C177-4D72-BF75-64CEDA37333EQ39256881-273CA40E-2D01-4C6A-AF47-E53AC72A5AD8Q39413648-A38707A0-D597-4D09-A807-27BC0EE27C8DQ41777376-F544169E-9AA5-48FE-BB7E-8DB92DB73D7CQ44020318-D0CF8488-3934-4665-9A72-D995F2277B07Q48236109-AAB31FA5-FF49-4B63-9250-75E4484AC000Q52722001-AF3A0A1A-44FC-49C6-B88D-B6CCFC1A9A93Q55411797-FC0F38C7-B9E1-427B-9E87-12A0E23CCB03Q57624742-22FB65BC-8995-44AF-9F25-CE5D10E68BF7
P2860
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
@ast
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
@en
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
@nl
type
label
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
@ast
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
@en
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
@nl
prefLabel
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
@ast
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
@en
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
@nl
P2093
P356
P1476
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
@en
P2093
Christopher Creech
Grant A McNaughton-Smith
Gregory C Rigdon
J Ford Burns
Jonathan W Stocker
Lucia de Franceschi
Susan Arrington
Tara Shelton
P304
P356
10.1021/JM070663S
P407
P577
2008-01-31T00:00:00Z